Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Chugai attributes the success of its development program for the novel interleukin-6 receptor-inhibiting Actemra (tocilizumab) to its partnership with Roche, Chugai Business Development General Manager Kimio Nishimura told Biomedical Asia 2008 attendees in Singapore April 16
You may also be interested in...
Japan's Biennial Price Cuts Spare Innovation But Punish Overachievers
Eisai took the biggest hit in the latest price revisions due to its lead products exceeding peak sales in Japan, according to analysts.
Japan's Biennial Price Cuts Spare Innovation But Punish Overachievers
Eisai took the biggest hit in the latest price revisions due to its lead products exceeding peak sales in Japan, according to analysts.
Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?
Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.